Refine by
Drug Target Equipment & Supplies
165 equipment items found
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI ...
Manufactured by:Systasy Bioscience GmbH based inMunich, GERMANY
The proprietary splitSENSOR technology is a highly sensitive,flexible and easy-to-use reporter assay system to monitor various cellular events in living cells, including the activity of drug targets. Various cellular events, such as regulated protein-protein interactions, can be robustly and quantitatively measured both at the membrane and in the cytosol of the ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Agonist refers to substances that activate a specific target protein. It can easily be viewed as the opposite of inhibitor. Until now, Deargen's drug-target interaction (DTI) was predicted based on the binding affinity between the substance and the target protein, which causes barrier to distinguish between the inhibition and ...
Manufactured by:Symberix, Inc. based inDurham, NORTH CAROLINA (USA)
Trillions of microorganisms colonize the human body and play a central role in health and disease. Symbiotic drugs target bacteria to improve human health while leaving good microbes ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug ...
Manufactured by:G3T Therapeutics based inMidlothian, VIRGINIA (USA)
All drugs targeting cardiovascular disease currently on the market work by lowering cholesterol levels. G3T identified and genetically validated an entirely novel biological mechanism and potential drug target that treats both cardiovascular disease, as well as non-alcoholic fatty liver disease. ...
Manufactured by:Inoviem Scientific SAS based inIllkirch-Graffenstaden, FRANCE
Identify the mode of action of your compound with NPOT® technology; NPOT technology is a unique heterogeneous assembly method for conducting extensive identification of all proteins (together with their native structure) involved in drug-target ...
Manufactured by:PharmaBlock Sciences (Nanjing), Inc. based inNanjing, CHINA
DNA-Encoded Library Technology (DELT) is a fast-growing, cutting-edge discovery technology used to identify small molecule hits or leads against a variety of drug targets. The main principle of DELT is to encode each compound in the library with a unique DNA barcode. Thereby library of billion compounds can be screened as a mix in a single test tube and the ...
Manufactured by:Isarna Therapeutics GmbH based inMunich, GERMANY
Because TGF-β is chronically elevated in many diseases, including ophthalmic and fibrotic diseases and cancer, and involved in their pathophysiology, it is an extremely versatile drug target throughout the body. ...
Distributed by:MoBiTec GmbH based inGoettingen, GERMANY
COVID-19 Research: Antiviral Drug Target ? The COVID-19 pandemic is caused by infection of SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2, a positive-sense single-stranded RNA virus. The RNA dependent RNA polymerase (RdRp) is a key drug target for this deadly virus. ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody ...
Manufactured by:GENFIT based inLoos, FRANCE
Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
IDH1/2 mutations are linked to abnormal histone and DNA methylation which may cause altered stem cell differentiation and eventual tumorigenesis. The unique features of IDH1/2 mutations make them good biomarkers and promising drug targets. ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. ...
Manufactured by:OPKO Health, Inc. based inMiami, FLORIDA (USA)
This strategy is unique and contrasts with established approaches which down-regulate protein production. This platform can lead to the discovery of new drugs to target relevant genes that regulate the optimal production of endogenous functional proteins. One of the leading applications of our AntagoNAT technology is OPK88001 which is designed for the treatment ...
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for [18F]-choline (FCH). ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...